Neonatal hypoxia-ischemia (HI) is one of the major causes of death and/or lifelong neurobehavioral and cognitive dysfunction. Undoubtedly, brain damage following HI insult is a complex process with multiple contributing mechanisms and pathways resulting in both early and delayed injury. It is increasingly recognized that one of the leading pathogenic factors of neonatal brain damage is inflammation, induced by activation of the central and peripheral immune system. Immune responses are induced within minutes and can expand for weeks and even months after the insult. Both activated intrinsic (glia) and infiltrating cells (mast cells, monocytes/ macrophages) produce soluble inflammatory molecules such as cytokines, chemokines, reactive oxygen, and nitrogen species, which are thought to be pivotal mediators of persistent neuronal injury. This manuscript provides a brief summary of the current knowledge concerning the specific contribution of different cell types and soluble factors to injury of the developing brain caused by neonatal HI. Finally, we discuss the potential forthcoming treatments aimed at targeting inflammation and then attenuation of damaging effects caused by neonatal HI.
INTRODUCTION
Neonatal hypoxic-ischemic (HI) encephalopathy (HIE) still remains one of the most important causes of neonatal mortality and/or long-term neurologic sequelae such as cerebral palsy, cognitive and intellectual deficits, and behavioral problems. In many cases perinatal hypoxic-ischemic insult most likely results from acute episodes of intrapartum asphyxia. Hypoxemia joined together with a substantial reduction in blood flow and in consequence insufficient glucose delivery to the highly vulnerable developing brain, triggers a chain of metabolic reactions, which can lead to extensive brain damage (1) (2) (3) . The initiation and the development of injury to the neonatal brain is a complex process, with multiple contributing mechanisms and pathways resulting in both early and delayed injury. It is generally accepted that one of the major pathogenic factors in the perinatal ischemic brain damage is inflammation induced by the activation of the peripheral and central immune system. Both activated intrinsic (glia) and infiltrating cells (mast cells, monocytes, and macrophages) produce several proinflammatory factors (cytokines, chemokines, nitric oxide synthase [NOS] , reactive oxygen species (ROS), excitatory amino acid agonists, and death receptor agonists) which could affect brain development with long-lasting consequences causing neurologic and/or mental health disorders (4) (5) (6) (7) (8) . Inflammatory signals are generated within minutes after the hypoxic-ischemic insult and can expand for weeks and even months (9) (10) (11) with specific contribution to different cell types. Some activated signal transduction pathways may result in injury to axons and myelin, the loss of oligodendrocyte progenitors, mature oligodendrocytes, and neurons (12) . The pathophysiologic role of inflammation has been supported by some clinical studies showing an increase in cytokine and chemokine serum levels in newborns with ischemic brain injury. Moreover, it is thought that the overexpression of inflammatory molecules might be associated with both cerebral damage and prognosis (13) (14) (15) .
The specific contributions of different cell types to brain inflammation as well as soluble mediators of inflammatory response in HIE continue to be a focus of many investigations during the last years (7, 8, (16) (17) (18) (19) . This review contains a brief summary of the current knowledge about the inflammatory response mechanisms participating in acute HI injury of the developing brain. We also discuss the anti-inflammatory potential of some pharmacologic agents.
CELLS PARTICIPATING IN INFLAMMATION

Microglia/Macrophages
The inflammatory response to brain hypoxia-ischemia is driven primarily by microglial cells. Under physiologic conditions in the central nervous system microglia exist in a ramified state, considered previously as a "resting" form. Later, these cells present highly motile processes that actively surveil their milieu, constantly sensing changes in the microenvironment and thus are able to maintain CNS homeostasis (20) (21) (22) . In reaction to neonatal HI ramified microglia proliferate and transform gradually into reactive cells. This process is generally referred to as microglial activation and proceeds through several steps characterized by changes in cellular morphology, cell size, cell number, and in cell surface protein expression. During the first stage of microglial activation these cells become hypertrophic (often called activated microglia), enlarged, hyper-ramified, or with short thick processes. They also change the expression of various enzymes and receptors and begin to produce immune response molecules. Finally, microglia lose their ramified morphology and surveillance mode, and convert to amoeboid-like functional cells, with an enlarged body and few to no processes (23, 24) . Active microglial cells migrate to the site of injury, and act in concert with recruited monocytes/ macrophages to elicit an immune response (Fig. 1 ). Both cell types play an important role in the proinflammatory cytotoxic reaction at least at the initial phase after the insult (5) (6) (7) (25) (26) (27) . Consistent with this there is overwhelming experimental evidence that the reduced microglial activation is associated . Inflammatory response to hypoxia-ischemia. In response to hypoxia-ischemia resting/ramified microglia proliferate and undergo activation. During the first step microglia become hypertrophic, enlarged, and hyper-ramified and then convert to amoeboid-like cells. Upon intensive acute signals these cells produce proinflammatory agents (among them cytokines and reactive oxygen species) that cause disruption of the immature blood-brain barrier (BBB). As a result peripheral immune cells (neutrophils, monocytes, lymphocytes) infiltrate the brain leading to exacerbation of inflammation and neuronal injury.
with diminished brain damage (28, 29) . Nonetheless, it is also known that inflammatory signals are an important innate mechanism responsible for elimination of pathogens and debris, and assist in tissue repair by maintaining neurogenesis after an acute injury to the brain. Thus, the complete suppression of microglial activity might result in more extensive brain damage after ischemic injury (30, 31) . Not so long ago, it was found that depending on the surrounding micro-environmental signals, microglial cells are capable to acquire distinct phenotypes presenting diverse activation states and different modes of action. The microglial phenotypes were classified by Colton (32) as either proinflammatory M1 (the so-called "sick") or anti-inflammatory M2 (called "healthy"). The proinflammatory M1 phenotype favors the production and release of inflammatory mediators (cytokines, chemokines, ROS, NO, matrix metalloproteinases) which collectively cause oligodendrocyte and neuronal death (24, 33, 34) . In contrast to the M1 action, M2 displays both immunosuppressive and neuroprotective properties due to the release of anti-inflammatory as well as neurotrophic factors (such as IGF, transforming growth factor [TGFb] , GDNF, and IL-10) that promote angiogenesis, tissue remodeling, and neurorepair (32, (35) (36) (37) (38) (39) (40) (41) . Animal studies of adult brain in ischemia show that at the early stages of ischemic stroke local microglia and newly recruited macrophages assume the M2 phenotype but they are transformed later into the M1 which evokes an inflammatory and cytotoxic response (33, 42) . In line with this remain our recent results showing a high number of M1 microglial cells with a significantly decreased number of cells representing M2 phenotype after neonatal HI (43) . The transition is accompanied by expression of novel surface antigens and production of phenotype-specific mediators.
To confirm the role of the microglial reaction to HI in the developing brain, in particular the time-course of M2 to M1 phenotype polarization and vice versa, further studies will be needed. Nevertheless, it seems logical to state, that effective ischemia therapies should be shifted from efforts aimed to reduce microglial/macrophage numbers toward adjusting the equilibrium between both microglia/macrophage phenotype responses.
Astrocytes
The reactive astrocytosis also appears to be a part of the developing ischemic brain injury (44, 45) . Immediately after the HI insult astrocytes are activated, undergo morphologic changes (hypertrophy) proliferate and show an increase in glial fibrillary acidic protein expression, culminating in the formation of glial scars in the damaged HI hemisphere (43, 45) . The role of reactive astrogliosis in the evolution of ischemic brain lesion, especially in neonates, is at present unclear. In contrast to the potential proinflammatory cytokine release, astrocytes are also known to be a source of anti-inflammatory mediators. Indeed, there are studies indicating that reactive astrocytes restrict inflammation preserving the surrounding neuronal tissue (46) . Furthermore, failure of astrocyte functions may contribute to neuronal degeneration (47, 48) .
It is worthy to note the recent discovery of Gabel et al (49) who showed that activation of inflammation promotes a conversion of astrocytes in vivo toward the more immature state, characterized by re-expression of stemness markers and the repression of typical astrocyte markers. Thus, such response may positively influence neural cell proliferation, survival, migration, and differentiation. Although results obtained from experiments in adults cannot be directly transferred and used as an explanation for neonatal data due to differences in the level of maturation and different ischemia models, some hypotheses can be valid in adult as well as in neonates.
Taken together all the current data it seems reasonable to suppose dual and opposite roles of astrocytes after neonatal HI. On one hand they can contribute to enlarged brain damage due to production of potential inflammatory and neurotoxic substances (cytokines, iNOS) (47, 48) , and on the other hand they may also release cytokines which have anti-inflammatory effects. The relative contribution of proinflammatory and antiinflammatory mechanisms in astrocytes depends probably on the degree of the insult and the time of recovery.
Neutrophils
There are many studies on adult brain that support the hypothesis of neutrophil recruitment as an important contributor to the evolution of ischemic brain injury (50, 51) . Compared with adults, neonates demonstrate a diminished ability to mount a neutrophil response. It was found that invasion of neutrophils to the injured brain tissue after HI is limited and the reported results are inconsistent (4, 52) . Nevertheless, neutrophils have been seen in blood vessels during the first few hours after HI (4, 53) . Moreover, depletion of neutrophils (neutropenia) before HI reduces brain swelling (53), whereas removing circulating neutrophils 4-8 h after HI does not cause any improvement (54) . Also, inhibition of NADPH required for phagocytosis by neutrophils, as well does not confer neuroprotection in neonatal mice (55) . Furthermore, it does not modify chemokine-neutrophil signaling, a pathway that presents protective ability against stroke in adult rats. Although the contribution of neutrophils to stroke injury in adult rodents has been proven, their engagement in neonatal brain damage has not yet been established.
Mast Cells
Recent findings of Jin et al (56) have pointed to mast cells as promoters of inflammation after neonatal HI. Due to migration of these cells to the HI hemisphere and then proliferation, their number rapidly and persistently increases (for days and weeks) in the damaged ipsilateral side. Regarding the molecular mechanism, mast cells are believed to act primarily by releasing inflammatory TNF and IL-9 (57). The deleterious role of these cells is supported by experiments using the mast cells stabilizer sodium cromolyn, which inhibits their activation. The observed response indicates mast cells as an important contributor to the developing ischemic injury (5, 56) .
MEDIATORS OF INFLAMMATION Cytokines
Although cytokines can be found in almost any nucleated cell within the brain, such as brain endothelial cells or neurons, they are mainly produced by glial cells or by immune cells, such as helper T cells. Systemic cytokines are often classified as proinflammatory (IL-1, IL-9, IL-18, TNFa, and IFNc), while cytokines that antagonize their responses include IL-4, IL-10, IL-11, and IL-13, and TGFb. There is an exception from this concept and IL-6 appears in both categories and can either propagate or downregulate inflammation, depending on the context (58) . Inflammatory cytokines, acting in concert with chemokines, have been proposed as crucial mediators of neonatal brain injury via inflammatory pathways triggered by hypoxia-ischemia (58) . Emerging data have demonstrated the association between cytokine profiles with HIE disease severity in animals and humans (58) (59) (60) (61) (62) (63) . Biologic effects of these factors include stimulation and synthesis of other cytokines, and prompting leukocyte infiltration, which in turn leads to the induction of neuronal injury mediators and influences glial expression (64) . Cytokine levels present large individual variations after neonatal HI and not all of them present elevated expression (43) . Depend on the experimental protocol, cytokines peak usually within 12-24 hours postinsult, but some of them have shown a biphasic pattern and may contribute to the early as well as to the ongoing secondary neuronal injury (61) . Growing evidence indicates that damaging processes that occur in the late postischemic stages are connected with the proinflammatory cytokines released by active microglia. This statement has gained support from the neuroprotective therapies targeting microglial activation after HI insult in neonates (65) (66) (67) (68) (69) (70) (71) .
IL-1b
IL-1b is widely recognized as one of the major regulator of early as well as late stages of brain damage associated with inflammation after hypoxic and ischemic injuries (72) (73) (74) (75) (76) . Several studies demonstrate that neonatal hypoxia-ischemia results in a rapid and sustained increase in expression of IL-1b mRNA and protein (43, 56, (77) (78) (79) in the damaged ipsilateral hemisphere, compared with sham control. The elevated level of IL-1b was also observed at longer reperfusion time (6 and 14 days). Such a delayed response suggests ongoing inflammation which may lead to permanent neuronal injury (78, 80) . It is worth while to point out that although IL-1b is thought to be nontoxic to oligodendrocyte lineage cells, it can stop proliferation and in consequence may delay white matter development and recovery after the insult (81) . IL-1b is believed to act primarily through transcriptional activation of iNOS gene (82) and NO generation (83, 84) , and by these can exacerbate brain injury. In support of this harmful action of IL-1b it was shown that administration of either type I interleukin receptor (IL-R1) antagonist or blocking antibodies ameliorates damage induced by excitotoxicity and/or ischemia (79, 85, 86) . The beneficial effect associated with down-regulation of IL-1b includes inhibition of microglial activation, neutrophil infiltration, and reduction of cytokine levels. It is important to know that IL-1b knockdown by lentivirus in vivo can reverse cell swelling, brain edema, and neurologic function deficiencies induced by neonatal HI (87) . Thus, it is tempting to speculate that IL-1b cytokine may be a target for gene therapy in neonates suffering from HI.
IL-9
The published data (56, 88) sheds light on the contribution of IL-9 in HI and excitotoxic brain injury in the developing brain. It also occurs that IL-9 mediates mast cell injury exacerbation in an excitotoxicity model in newborn mice (88) . It has been shown that IL-9 inhibits postmitotic neuron apoptosis in the newborn mouse cortex (89) . In fact, the respective action of IL-9 has not been settled with regard to HI insult and this subject needs further investigation.
IL-18
IL-18 is a proinflammatory cytokine from the IL-1 family that becomes active upon cleavage by caspase-1 in a way similar to that for IL-1b. IL-18 is produced preferentially by activated microglia and astrocytes. Its expression is increased after neonatal HI (80) . This cytokine has been found to play an important role in the development of white matter injury (90) . Genetic deletion of this cytokine appears to be neuroprotective in neonatal HI injury, demonstrating higher expression of myelin basic protein following the insult, in comparison to wildtype mice. Interestingly, IL-18 elimination more efficiently protects the neonatal brain from HI than genetic knock-out of IL-1b (80).
IL-4
IL-4 is commonly thought to possess anti-inflammatory abilities. However, the data relating action of IL-4 are very scarce. Based on the finding that treatment of P5 rodents with IL-4 prior to induction of excitotoxicity does not exacerbate injury, it is tempting to speculate that IL-4 contributes to endogenous protection in a newborn brain (91) .
IL-10
IL-10, similarly to IL-4, is generally accepted as an antiinflammatory cytokine. Its level increases prominently after HI (77) . An anti-inflammatory and protective effect of IL-10 against neuronal death after experimental HI in newborns was noted only in the case when exogenous cytokine was administered after the insult, whereas treatment prior to or at the time of the injury occurred to be ineffective. Moreover, the use of either anti-IL-10 antibody or IL-10 knock out mice did not demonstrate any beneficial effect (92) . It is postulated that IL-10 can reverse injury in neonates caused by IL-1b, TNF-a, and IL-6 (92). The most probable and consistent with the already established function of IL-10 is its ability to reduce macrophage accumulation in the injured brain.
IL-6
IL-6 can potentially exert beneficial and/or detrimental effects depending on the pathologic context (58, 93) . While in the acute phase of ischemia-induced changes in adult rodents IL-6 functions as a mediator of inflammation, between subacute and prolonged phases it acts as a neurotrophic mediator (93) . Mounting evidence suggest that the neuroprotective action observed in several types of brain injury (in vivo and in vitro) is mediated via leukemia inhibitory factor and ciliary neurotrophic factor (94) (95) (96) . This positive response is consistent with an improvement in neuronal cell survival after NMDA treatment and with protection against apoptosis (95, 97, 98) . In the neonatal brain, IL-6 appears transiently several hours after the insult (99) and blocking its action protects the injured brain (79) . However, the lack of notable differences between ipsilateral (hypoxic-ischemic) and contralateral (hypoxic) hemispheres at an early and late phase postinjury does not allow to establish its function after neonatal HI (43) and may also open questions regarding the role of this cytokine.
IFNc
Although evidence is growing for the importance of IFNc in neuronal development, only limited data are available on the role of this cytokine after HI. According to the existing knowledge IFNc originating from activated macrophages/ microglia and reactive astrocytes may coordinate the cellular immune and inflammatory responses in the central nervous system through the induction and interaction with other cytokines (100). Therefore, it seems logical to anticipate its dual role (protective as well as destructive), both of which are closely associated with the level and timing of its expression. The level of this cytokine was found to be increased 6 to 72 hours after birth in the cord blood in cases of white matter damage in human perinatal brain injury (101, 102) . IFNc is known to activate macrophages/microglia to produce other proinflammatory cytokines, such as TNFa and interleukins (103) and thus participates in the cytokine-induced toxicity to developing oligodendrocytes in human perinatal brains (103) . The molecular mechanism of its action includes generation of ROS and lipid peroxidation, which lead to toxic injury (102) . On the other hand, the reported data indicate an important role of IFNc in neurodevelopment, in neuronal survival, differentiation, and process outgrowth, as well as in myelin formation. It was even postulated that IFNc potentially protects the brain from ischemic injury by reducing apoptosis in oligodendrocyte progenitors (104) and astrocytes (92) of rodent origin. In summary, the data reported till now regarding the role of IFNc are controversial and require further detailed study.
TNF-a
The pathophysiologic role of TNF-a as an inflammatory mediator in neonatal stroke is assumed, but has yet to be proved. Under physiologic conditions TNF-a induces growth and proliferation of some cells by binding to TNF-R2 receptor and activating the associated with survival Akt signaling pathway (105, 106) . In contrast, as noted in several reports, excessive expression of TNF-a in pathologic conditions may induce apoptosis in cells via binding to its receptor TNF-R1 and activating caspase signaling pathways (107) . Therefore, the TNF-a actions mediated through two receptors, which activate distinct signaling pathways, make the assessment of its role after injury more complex. A significantly increased amount of TNF-a was observed at early time of recovery following HI in the hypoxic-ischemic hemisphere, which suggests its action in the early phase after the insult (43) . In addition, increased expression of TNF-R1 on oligodendrocytes after hypoxic exposure in neonatal rats may suggest induction of apoptosis and delayed myelination (75, 108) . The potential deleterious activity of TNF-a has been confirmed also in vitro by reduced survival and maturation of oligodendrocyte progenitors (104) .
Chemokines
Chemokines are a family of small proteins (8-10 kDa) belonging to 4 classes: C, CC, CXC, and CXC3, based on the position of key cysteine residues. Despite the number of reports focusing on the role of cytokines, in particular the role of IL-1b, only a few data are available on the potential role of chemokines in the development of HIE (109, 110) . It has been found that mRNA expression of several chemokines such as macrophage inflammatory protein-1 (MIP-1a and MIP-1b) precedes infiltration of immune cells into the brain, thus proving their relevance in the inflammatory response (4). The expression of another chemokine, macrophage chemoattractant protein (MCP)-1/CCL2, as well as its receptor CCR2 also increases following HI and excitotoxic injury in the neonatal brain. It is suggested that these molecules may regulate microglial recruitment and activation during the brain insult as well as extravasation and transmigration of monocytes under inflammatory conditions (111) . The pathophysiologic role of MCP-1 in neonatal brain injury is evident from experiments using protection by functional inactivation of MCP-1 after insult or with depletion of IL-1 converting enzyme (109, 112) . The activity of CCR2 receptor may present also immunomodulatory and protective functions during central nervous system inflammation. The beneficial effect of CCR2 may be associated with its engagement in the migration of neuroblasts to the damaged region of the brain.
Only a few studies have been performed to clarify the involvement of CXC chemokines in perinatal HI. A significantly increased amount of chemokine CXCL10 (IP10) was observed early in the ipsilateral hemisphere compared with control. The concentration of chemokine remained elevated up to 6 days of survival time. In contrast, the level of these molecules in the contralateral side did not differ from the controls (43) . The data reported by Donega et al (113) show a significant upregulation of CXCL10 gene expression following neonatal HI. It is supposed that CXCL10 may play an important role in regulating homing of mesenchymal stem cells to the lesion site. Therefore, the question arises if immunomodulatory intervention may have a negative effect upon specific aspects of neurogenesis, and thus, brain regeneration.
Stromal cell derived factor-1 (SDF-1) (CXCL12) is another CXC chemokine which may play an important role in homing stem cells to regions of ischemic injury (114) . Moreover, SDF-1 is considered as a beneficial mediator of brain repair by increasing neurogenesis after ischemia in adult rodents (115) . However, the prolonged upregulation of this cytokine in neonates has not been observed.
Nitric Oxide
Nitric oxide (NO) emerges as an important mediator in the pathogenesis of neonatal brain HI. However, in spite of a full agreement relating the enhancement of NO production after neonatal HI, the data regarding kinetics of changes in expression of NOS isoforms are conflicting. According to the existing data NO production in the brain after HI may play either a neurotoxic or a neuroprotective role. The function of NO clearly depends upon factors such as the isoform of NO synthase, the cell type by which NO is produced, and the timing of its generation. Studies have shown that elimination of genes encoding neuronal or inducible NOS (nNOS and iNOS, respectively) result in reduction of brain damage caused by hypoxia-ischemia (116, 117) . In contrast, animals lacking the endothelial NOS (eNOS) gene demonstrate larger cerebral infarct after the injury (118) . In spite of this, excessive NO production can lead to a direct damage of cell constituents by producing a number of toxic species such as peroxynitrate, activated COX-2 or inflammatory cells (109) .
Transcription Factor NF-jB
Transcription factor nuclear kappa B activated in neonatal brain after hypoxic-ischemic insult has been shown to increase transcription of several major genes involved in inflammation such as proinflammatory cytokines, chemokines, TNF-a, adhesion molecules, and inducible NOS (120, 121) , that could contribute to neuronal damage. It is commonly accepted that inhibition of NF-jB prevents proinflammatory cytokine production, thereby contributing to neuroprotection (122, 123) .
On the other hand NF-jB may upregulate some antiapoptotic factors (Bcl-2 and Bcl-XL), increase the expression of neurotrophins (e.g. nerve growth factor [NGF]) and SOD and by this can contribute to cell survival (124, 125) . According to the interesting results reported by Nijboer et al (126) it appears that NF-jB can play time-dependent specific role: the early postinsult NF-jB activation contributes to neonatal HI brain damage, whereas the late action of this factor promotes neuronal survival by upregulation of antiapoptotic molecules.
Cyclooxygenases
Cyclooxygenases are key mediators of inflammation in different forms of brain injury including neonatal HI. Both cyclooxygenases, inducible cyclooxygenase-2 (COX-2) and constitutive cyclooxygenase-1 (COX-1), catalyze the synthesis of prostaglandins (PG). Cerebrospinal fluid concentrations of prostaglandins (PGE2 and PGI2) have been reported to be significantly higher in children with perinatal hypoxia (127) . The binding of prostaglandins to specific receptors and activation of distinguishing signaling pathways may result in damaging as well as in protective effects (128, 129) . Pharmacologic inhibition of COX-2 has been shown to be beneficial in brain and spinal cord-related injuries in adults (130) . Importantly, the protective effect of COX-2 inhibition was also reported in neonatal rodents subjected to HI (131).
Anti-Inflammatory Strategies and Neuroprotection
It is commonly thought that blocking the inflammatory reaction confers neuroprotection and has potential for use in clinical treatment of ischemic brain injury (65-67, 132, 133) .
A variety of drugs targeting neuroinflammation have been tested in animal models of perinatal brain injury, however, translating them from bench to the bedside has been limited. First of all, delivery across blood-brain barrier was an important consideration. However, alternative delivery methods such as nanoparticles facilitate targeting the inflammatory system (134) (135) (136) . It is widely known that most of the drugs tested have multiple or even pleiotropic effects that go beyond pure anti-inflammatory action, including antioxidant and antiapoptotic properties and induction of neuro-or angiogenesis. Therefore, it is difficult to definitively link the neuroprotective properties of these drugs with their anti-inflammatory properties. While in many, but not in all cases, protection is associated with reduced macrophage densities in injured regions, in a growing number of cases protection occurs through an antiapoptotic mechanism without directly affecting activation of inflammatory pathways, such as cytokine or NO, a phenomenon shown for minocycline (137) (138) (139) , iNOS inhibitor 2-iminobiotin (140), chloroquine (29) , and aminoguanidine (141) . Thus, substantial work is needed to understand the interplay between injury, neuronal cell death, and inflammation. Because HIE is a very heterogeneous and complex process, finding the ideal method to study these interactions remains a difficult task. In spite that several models of hypoxia-ischemia have been developed in rodents and in larger species [see review (142)] obviously none of them can sufficiently mimic the complex human pathophysiology. Although, biologic proximity to humans seems to be important in animal studies, the experiments in general have been performed in rats and mice. It is worth mentioning that rodent physiology and white/ grey matter ratio is different from that in humans. Another challenge is to establish the proper dose, mode and timing of drug application, since therapeutic targets might alternate in the phases of hypoxic-ischemic encephalopathy, in addition to the physiologic development changes that occur in neonates over time (143) . Progressive research might improve and optimize future treatment demanding personalized clinical pharmacologic and physiologic understanding.
Erythropoietin
Of the agents with anti-inflammatory actions and a potential use for clinical application in the near future, erythropoietin (EPO) is the most and up to now only attractive candidate (144) . EPO is a pleiotropic cytokine originally identified for its role in erythropoiesis and has been suggested to have neuroregenerative, angiogenic, anti-inflammatory, and antiapoptotic properties in the brain (145) (146) (147) (148) . EPO exerts its antiinflammatory action after binding to its receptor expressed on the membranes of neurons, astrocytes, and microglial cells (149) . Numerous experimental studies in different neonatal species showed its neuroprotective properties in posthypoxicischemic brain damage (149) . Clinically, a pilot study of 45 patients showed that treatment of asphyxiated newborns with recombinant human EPO (rhEPO) seemed safe and feasible (150) . On the other hand, it was found that rhEPO treatment of 21 neonates with diagnosed perinatal arterial ischemic stroke did not affect the volume of brain damage (151) . It is worth to point that this study was performed on a small population of patients. Larger studies are required to precisely define the effect of this agent.
Melatonin
Melatonin has multiple targets in the injury cascade and is a perfect candidate for manipulating inflammation. In addition to its antioxidative and free radical scavenging actions melatonin is also supposed to have anti-inflammatory properties by preventing activation and translocation of NF-jB to the nucleus and markedly decreasing microglial activation (152, 153) . The study in piglets revealed that melatonin, in combination with hypothermia provided substantial improvement in preserving brain function and reduced cell death. Although melatonin seems to be safe and without serious adverse effect there is no consensus in the optimal dosing (154) . There are still ongoing clinical trials examining this issue (NCT02621944).
Doxycycline
Doxycycline significantly inhibits neuroinflammation. The anti-inflammatory properties of doxycycline are independent of its antimicrobial function, and it is thought to exert its beneficial effects in part through the inhibition of microglial activation and reduction of IL-1b and TNF-a expression. It also augments BDNF following HI (155) . Importantly, doxycycline, is approved for use in neonates, and compared with other drugs of this class, has a lesser side-effect profile (156) . The results of experimental work suggest a putative clinical potential of doxycycline in the management of neonatal cerebral HI injury (155) .
Minocycline
Minocycline is a tetracycline derivative that has been shown to be safe and effective as an anti-inflammatory drug for treating inflammatory conditions. Unfortunately, minocycline has also been shown to have variable and even detrimental effects in different species and models of neurologic disorders (29, (157) (158) (159) . Minocycline is not approved for use in neonates due to a significant side-effect profile (156, 160) .
Cannabidiol
Cannabidiol, the main nonpsychoactive component of Cannabis Saliva, has recently been included among the pleiotropic therapies, as it has been shown to reduce HI-induced brain damage in newborns (rats and piglets). It has a shortterm effect by modulating inflammation, excitotoxicity, and oxidative stress (69, (161) (162) (163) (164) (165) . However, the duration of the follow-up appears to be time-limited to evaluate long-term neurobehavioral consequences. Thereby it is ahead of time to achieve a clinical trial.
Cyclooxygenases (COX-2)
Currently, selective inhibitors of COX-2 have emerged as an important class of drugs because of diminished incidence of side-effects when compared with several nonsteroid anti-inflammatory drugs. In addition, COX-2 inhibitor, celecoxib, used in clinic, has been rapidly cleared in children when compared to adults (166) . Studies reported by Fathali et al (131) show that treatment with COX-2 inhibitor NS-10 has a neuroprotective activity in a model of neonatal hypoxiaischemia. It leads to a marked decrease in inflammatory cell infiltration, such as macrophages and neutrophils, and to a lower activation of microglia as well as expression of IL-6 in the injured brain tissue. Thus, selective COX-2 inhibitors may be considered as one of the valuable treatment options.
Resveratrol
Resveratrol (3, 4 0 ,5-trihydroxystilbene) is a naturally occurring polyphenolic compound, and has broad physiologic and pharmacologic properties, including a strong antiinflammatory action (167, 168) . The experimental studies in vivo show neuroprotective effects in neonatal HI brain injury associated with the inhibition of inflammation by diminishing key inflammatory factors. It seems to be a promising therapeutic strategy for treatment of neonatal HI brain injury (169) . Furthermore, several studies have investigated the drugs' effect on the CNS in human adults and no adverse events have been reported in the majority of the studies (170, 171) .
Histone Deacetylase Inhibitors
Mounting evidence has pointed to broad acting inhibitors of histone deacetylases (HDACs) as anti-inflammatory agents. Early studies demonstrated that HDAC inhibitors such as trichostatin A (TSA) and phenylbutyrate modulate the expression of inflammatory genes involved in the pathogenesis of experimental rheumatoid arthritis (172) . The antiinflammatory and neuroprotective potency of HDAC inhibitors (TSA, sodium butyrate, valproic acid) have been later described in the ischemic adult brain (173) (174) (175) . A few available reports addressed their anti-inflammatory action in the hypoxia-ischemia injured immature brain (11, 26) . It occurred that the neuroprotective action of HDAC inhibitors are multifold and involve modulation of oxidative pathways and components of excitotoxicity, reduction of several inflammatory and proapoptotic factors. The broad action of HDAC inhibitors makes it difficult to determine which isoform of the HDAC enzyme is particularly important for inflammation. Since neonatal HI brain injury is complicated and targeting only one mechanism is far from sufficient, exploring the timing, dosage and routes of the drug administration as well as performing functional studies should be addressed in the future. Thus, it can be hypothesized that the pleiotropic actions of HDAC inhibitors are promising. In addition, new antiinflammatory immunomodulatory compounds continue to be identified and bring about increased hope for their use as a therapeutic option in infants with HI encephalopathy (69, 70) .
CONCLUSION
Neonatal HI insult triggers a cascade of biochemical events that ultimately cause cell death and life-long neurobehavioral and cognitive dysfunction. Brain damage following hypoxia-ischemia is a complex process, with multiple mechanisms and pathways leading to brain injury. One of the major pathogenic factors contributing to ongoing neonatal ischemic brain damage is inflammation through the action of proinflammatory mediators leading to the alteration of neuronal functions. Despite the fact that numerous in vivo and in vitro studies provide growing evidence that anti-inflammatory compounds show promising neuroprotective effects in animal models, only few of them have progressed to clinical trials. The application of potential neuroprotective agents has been truly restricted due to insufficiency or/and serious side-effects demonstrated by their impact on normal brain activity. However, even though animal models are poorly predictive of human outcomes, these experiments are mandatory especially in drug development. Therefore, the issue of discovering new compounds adapted hopefully in the future as a therapeutic option in infants with hypoxic-ischemic insult remains an ongoing challenge.
